Safety and Effectiveness of Intravenous Ferric Carboxymaltose for Moderate Anaemia in Pregnancy

Background: Anaemia in pregnancy is a major global health concern linked to adverse maternal and foetal outcomes. Intravenous ferric carboxymaltose (FCM) is a relatively new therapy that enables rapid correction of iron deficiency with minimal adverse effects.Aim: To evaluate the safety and effectiveness of intravenous FCM in pregnant women with moderate anaemia during the second and third trimesters.Methods: This prospective observational study was conducted at the Department of Obstetrics and Gynaecology of the Government Medical College in Srinagar, India, over 18 months. One hundred pregnant women with moderate anaemia (Hb 7–9.9 g/dL) received a single intravenous infusion of FCM (maximum 1000 mg). Haemoglobin and serum ferritin levels were measured before and four weeks after infusion. Adverse events and fetal outcomes were monitored.Results: Mean baseline haemoglobin was 7.81 ± 0.43 g/dL, which increased to 9.47 ± 0.48 g/dL (p < 0.001). Mean serum ferritin rose from 16.70 ± 6.97 ng/mL to 122.20 ± 15.98 ng/mL (p < 0.001). Only 2% of participants experienced minor allergic reactions; no serious maternal or fetal adverse events occurred.Conclusion: FCM is a safe and effective option for treating moderate anaemia in pregnancy, offering rapid correction with minimal side effects.